Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

First European launch in Denmark of Brintellix for Major Depressive Episodes- Lundbeck.

17-Sep-2014

H. Lundbeck A/S has now started the ...

Phase III data for Prolia in Osteoporosis-Amgen

17-Sep-2014

Amgen has announced results from a ...

Phase III trial of RLY 5016 for Hyperkalemia meets endpoints-Relypsa

17-Sep-2014

Relypsa Inc. has announced new data ...

Cochrane Collaboration report discounts safety issues of Avastin for Macular Degeneration- Novartis + Roche

17-Sep-2014

Cochrane Collaboration researchers ...

FDA approves Movantik for treatment of Opioid-Induced Constipation in patients with Chronic Non Cancer Pain. - AstraZeneca

17-Sep-2014

AstraZeneca has announced that the ...

Roche initiates Phase III trial for lampalizumab for Geographic Atrophy, a form of AMD.

17-Sep-2014

Roche announced that phase III ...

Analysis from SHIFT study confirms role of ivabradine in reduction of risk in Heart Failure-Amgen

16-Sep-2014

Amgen announced data from the Phase ...

Recent Updates

Drugs

Clinical Guidelines

Early and locally advanced breast cancer: Diagnosis and treatment

Advanced breast cancer (update): Diagnosis and treatment

Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care

Medical Journals

Targeting hypoxia in the treatment of small cell lung cancer

Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus

Criteria for the Diagnosis of Fibromyalgia: Validation of the Modified 2010 Preliminary American College of Rheumatology Criteria and the Development of Alternative Criteria

Clinical performance of Prostate Health Index (PHI) for prediction of prostate cancer in obese men: data from a multicenter European prospective study, PROMEtheuS project

epgonline.org Social